Analysts Set Immuneering Co. (NASDAQ:IMRX) Price Target at $13.50

Immuneering Co. (NASDAQ:IMRX) has been assigned an average rating of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $13.50.

Several equities research analysts have recently weighed in on the company. Guggenheim reissued a “neutral” rating on shares of Immuneering in a research note on Thursday, March 14th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $3.00 target price (down previously from $16.00) on shares of Immuneering in a research report on Friday, March 15th. TD Cowen reaffirmed a “market perform” rating on shares of Immuneering in a research report on Friday, March 15th. Oppenheimer reissued an “outperform” rating and set a $25.00 price objective on shares of Immuneering in a research report on Tuesday, March 5th. Finally, Chardan Capital reduced their price objective on Immuneering from $21.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, March 15th.

Insider Buying and Selling at Immuneering

In other Immuneering news, major shareholder Cormorant Asset Management, Lp sold 509,091 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $3.72, for a total transaction of $1,893,818.52. Following the transaction, the insider now directly owns 3,695,273 shares in the company, valued at $13,746,415.56. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, major shareholder Cormorant Asset Management, Lp sold 509,091 shares of Immuneering stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $3.72, for a total value of $1,893,818.52. Following the transaction, the insider now directly owns 3,695,273 shares in the company, valued at $13,746,415.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Benjamin J. Zeskind acquired 20,000 shares of the company’s stock in a transaction dated Tuesday, March 19th. The stock was acquired at an average price of $2.77 per share, for a total transaction of $55,400.00. Following the completion of the purchase, the chief executive officer now directly owns 2,281,852 shares of the company’s stock, valued at approximately $6,320,730.04. The disclosure for this purchase can be found here. Insiders have purchased a total of 111,790 shares of company stock worth $266,645 over the last three months. Corporate insiders own 23.00% of the company’s stock.

Hedge Funds Weigh In On Immuneering

A number of institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD increased its stake in shares of Immuneering by 16.2% in the second quarter. Price T Rowe Associates Inc. MD now owns 4,142,829 shares of the company’s stock worth $22,413,000 after purchasing an additional 577,356 shares during the period. BlackRock Inc. grew its position in Immuneering by 80.8% during the second quarter. BlackRock Inc. now owns 2,423,658 shares of the company’s stock worth $24,576,000 after buying an additional 1,083,465 shares in the last quarter. Citadel Advisors LLC grew its position in Immuneering by 1.8% during the second quarter. Citadel Advisors LLC now owns 2,199,209 shares of the company’s stock worth $11,898,000 after buying an additional 39,777 shares in the last quarter. Vanguard Group Inc. grew its position in Immuneering by 2.9% during the fourth quarter. Vanguard Group Inc. now owns 1,073,815 shares of the company’s stock worth $7,893,000 after buying an additional 29,963 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in Immuneering by 1,765.1% during the second quarter. Goldman Sachs Group Inc. now owns 488,863 shares of the company’s stock worth $4,957,000 after buying an additional 462,652 shares in the last quarter. 67.65% of the stock is currently owned by institutional investors.

Immuneering Stock Performance

Shares of IMRX stock opened at $2.10 on Tuesday. Immuneering has a 1 year low of $1.90 and a 1 year high of $14.29. The stock has a market cap of $61.49 million, a PE ratio of -1.11 and a beta of -0.89. The business’s fifty day moving average is $4.60 and its 200-day moving average is $5.91.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Friday, March 1st. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.06). Equities research analysts predict that Immuneering will post -1.89 earnings per share for the current year.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.